ArticleLiver international : official journal of the International Association for the Study of the Liver2025
Significant Decline in HCV-Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015-2022): A Sentinel Center Study.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Significant Decline in HCV-Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015-2022): A Sentinel Center Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundReducing mortality attributable to hepatitis C virus (HCV) is a key target in the World Health Organization (WHO) HCV elimination strategy. While liver cancer registration in Taiwan includes hepatitis C antibody (anti-HCV) status, no national registry records viral etiologies for deaths from liver cirrhosis and chronic liver disease (LC/CLD). Therefore, this sentinel study aimed to estimate national trends in HCV-related LC/CLD mortality.
methodsThe study period spanned from 2015 to 2022. According to ICD-10 codes K70, K73 and K74, the annual mortality numbers for LC/CLD were extracted from national biostatistics. Using the Chang Gung Research Database (CGRD), cases that died from LC/CLD with available results for both HBsAg and anti-HCV tests were included in the analysis. Based on the proportions of HCV distributions from CGRD, the national viral etiology-specific case numbers were estimated using a direct standardised method.
resultsA total of 35 413 patients died from LC/CLD nationally, with 15 445 of them having medical records in CGRD, and 5940 (16.8%) having results for both HBsAg and anti-HCV tests. The national case number was 4878 in 2015, decreasing to 4107 (-15.8%) in 2022. The proportion of anti-HCV decreased from 25.7% to 16.6% (-36.2%). Direct standardisation showed that the estimated national case number for anti-HCV decreased from 1424 to 811 (-43%).
conclusionsFrom 2015 to 2022, Taiwan experienced a 43% decline in HCV-related LC/CLD mortality, supporting progress toward national HCV elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.